Autonomix is aiming to shrink today's diagnostic lab equipment down to the size of a two-millimeter microchip placed on a catheter that can detect and target nerve signals.
This potentially groundbreaking technology is intended to be the equivalent of a GPS for the nervous system, which could unlock new treatments for everything from high blood pressure to pain. Imagine treating pain by altering the nerves instead of relying on prescriptions like opioids.
Autonomix's tech has over 100 patents, a strong edge against potential copycats as they tackle this estimated $100B market opportunity.
This message is a paid advertisement sent on behalf of Autonomix, a third-party advertiser of MarketBeat. Why did I receive this email?
This message is a paid advertisement for Autonomix from Autonomix and Strikepoint. American Consumer News, LLC dba MarketBeat receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $15,000. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Autonomix or Strikepoint. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Autonomix on their website for additional information about Autonomix and their Regulation A offering.
If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.
Post a Comment
Post a Comment